Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.

Family members, caregivers must take precautions from exposure to targeted drugs

17 Jul 2017
ETC-206 is a form of target therapy which specifically targets and inhibits Mnk enzyme in cancer cells.

There is a growing number of targeted therapies being approved for use in cancer therapy in the home setting, and this poses a potential risk among family member and caregivers, particularly those of reproductive risk age, a recent study suggests.

The findings show that most of the oral targeted therapeutics have not been tested for carcinogenicity and that the genotoxicity data are mixed. However, majority of these drugs show adverse reproductive effects, of which some are severe.

Furthermore, data that are currently available do not permit the possibility of a health hazard from inappropriate handling of drugs and contaminated patients’ waste to be ignored, especially in a long-term home setting.

There is a need for overall basic education and related precautions in order to protect family members and caregivers from indirect or direct exposure to these drugs, according to researchers, adding that further research and discussion on this subject are warranted.

In this study, researchers performed a systematic literature review and summarized the known adverse health effect of 32 oral targeted therapeutics. They particularly assessed the carcinogenicity, genotoxicity and embryo-foetal toxicity, together with the route of excretion.

“With the growing number of oral targeted therapies being approved for use in cancer therapy, the potential for long-term administration of these drugs to cancer patients is expanding,” researchers said.

“The use of these drugs in the home setting has the potential to expose family members and caregivers to them either through direct contact with the drugs or indirectly by exposure to the parent compounds and/or their active metabolites in contaminated patients’ waste,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Naomi Rodrig, 15 Jun 2016
An interim analysis from the multinational phase III CASTOR trial, presented recently at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, showed that adding daratumumab to the standard two-drug regimen of bortezomib and dexamethasone markedly improved outcomes of patients with recurrent or refractory multiple myeloma.
Saras Ramiya, 14 Nov 2017
Accord Healthcare launches Accord Bortezomib® (bortezomib 3.5 mg per vial) for the treatment of patients with multiple myeloma and mantle cell lymphoma in Malaysia.
Su Ping Chuah, 01 Aug 2014

New immune therapies with new targets that can induce long-term remission in patients with advanced cutaneous T-cell lymphoma (CTCL) are needed, says an expert.

Radha Chitale, 01 Aug 2014

German experts came together to update guidelines on melanoma management and create consensus out of fragmented standards of care by experts across multiple fields.